Is it safe to give an 81‑year‑old woman a 15 mg intramuscular dose of ketorolac (Toradol) while she is taking ticagrelor (Brilinta) instead of apixaban (Eliquis)?

No – Do Not Give Ketorolac (Toradol) to a Patient on Ticagrelor (Brilinta)

You should avoid administering ketorolac 15mg IM to this 81-year-old woman taking ticagrelor (Brilinta) due to significantly increased bleeding risk from the combination of antiplatelet therapy and NSAIDs.

Primary Concern: Compounded Bleeding Risk

The core issue is that both ticagrelor and ketorolac independently increase bleeding risk, and their combination creates additive—potentially synergistic—hemorrhagic complications:

Ticagrelor's Bleeding Profile

• Ticagrelor carries an FDA boxed warning for bleeding risk, including fatal bleeding 1
• The drug is specifically contraindicated in patients with active bleeding or history of intracranial hemorrhage 1
• Guidelines explicitly warn to avoid combination with NSAIDs due to increased bleeding complications 2

Ketorolac's Bleeding Profile

• Ketorolac causes platelet inhibition with altered hemostasis and gastrointestinal bleeding 3
• The risk increases substantially in elderly patients (your patient is 81 years old) 3
• Contraindications include "compromised hemostasis" and "risk of gastrointestinal bleeding" 3

Age as a Critical Risk Factor

At 81 years old, this patient faces:

• Higher baseline bleeding risk with antiplatelet therapy 2
• Increased susceptibility to NSAID-related adverse effects, particularly GI and intracranial bleeding 2
• Greater risk of acute renal failure from ketorolac 4

Why Brilinta vs. Eliquis Matters (But Doesn't Help)

The question implies that switching from apixaban (Eliquis, an anticoagulant) to ticagrelor (Brilinta, an antiplatelet) might make ketorolac safer. This is incorrect reasoning:

• While ticagrelor has a different mechanism than apixaban, it still significantly impairs hemostasis
• Guidelines treat antiplatelets and NSAIDs as a dangerous combination regardless of whether an anticoagulant is also present 2
• The 2014 AHA/ACC guidelines specifically state to "avoid combination of anticoagulants, thrombolytics, NSAIDs" with antiplatelets 5

Safer Alternatives for Pain Management

The 2014 AHA/ACC NSTE-ACS guidelines provide a stepped-care approach for chronic musculoskeletal pain in patients on antiplatelet therapy 5:

First-Line Options (Class I Recommendation)

1. Acetaminophen (paracetamol)
2. Non-acetylated salicylates
3. Tramadol
4. Small doses of narcotics (opioids)

Second-Line (Class IIa - Only if First-Line Inadequate)

• Nonselective NSAIDs (like naproxen) may be reasonable if initial therapy fails 5
• However, even this carries risk and should use the lowest effective dose for the shortest time 5

Critical Caveat

The guidelines explicitly warn against NSAIDs with "increasing degrees of relative COX-2 selectivity" in post-ACS patients 5. While ketorolac is non-selective, its potent antiplatelet effects make it particularly problematic.

Clinical Decision Algorithm

For this 81-year-old on ticagrelor needing acute pain relief:

1. First attempt: Acetaminophen 1000mg PO (if no hepatic impairment)
2. If inadequate: Add tramadol 50-100mg PO
3. If still inadequate: Consider low-dose opioid (e.g., oxycodone 5mg PO)
4. Avoid entirely: Ketorolac or any NSAID unless pain is refractory to all alternatives AND bleeding risk is formally assessed as acceptable

Additional Considerations

Renal Function

• Elderly patients are at heightened risk for ketorolac-induced acute renal failure 4
• This risk is amplified by volume depletion, pre-existing mild renal dysfunction, or congestive heart failure 4
• Check creatinine clearance before considering any NSAID

Duration Matters

• If an NSAID were absolutely necessary, duration should be limited to ≤5 days 3
• However, even short-term use carries significant risk in this population

Gastroprotection

• If NSAIDs cannot be avoided, proton pump inhibitors should be prescribed for GI bleeding prophylaxis 2, 5
• This is particularly important in patients ≥75 years on antiplatelet therapy 2

Common Pitfall to Avoid

Do not assume that because the patient is no longer on an anticoagulant (Eliquis), adding an NSAID is now safe. Ticagrelor alone creates sufficient bleeding risk that NSAIDs remain contraindicated. The combination of antiplatelet therapy + NSAID + advanced age creates a high-risk scenario for major bleeding, including intracranial and gastrointestinal hemorrhage 2, 5.